RESUMO
The development and operation of liquid-argon time-projection chambers for neutrino physics has created a need for new approaches to pattern recognition in order to fully exploit the imaging capabilities offered by this technology. Whereas the human brain can excel at identifying features in the recorded events, it is a significant challenge to develop an automated, algorithmic solution. The Pandora Software Development Kit provides functionality to aid the design and implementation of pattern-recognition algorithms. It promotes the use of a multi-algorithm approach to pattern recognition, in which individual algorithms each address a specific task in a particular topology. Many tens of algorithms then carefully build up a picture of the event and, together, provide a robust automated pattern-recognition solution. This paper describes details of the chain of over one hundred Pandora algorithms and tools used to reconstruct cosmic-ray muon and neutrino events in the MicroBooNE detector. Metrics that assess the current pattern-recognition performance are presented for simulated MicroBooNE events, using a selection of final-state event topologies.
RESUMO
Biochemical markers of bone turnover have for several years been considered as valuable parameters in research clinical studies, but their use in individual patients is still debated. Recently several position papers have proposed guidelines for their use in clinical practice in patients with post menopausal osteoporosis. In the present article, we report the results of a survey which aims at comparing the actual modalities of prescription of French physicians with the above-mentioned recommendations. We contacted by phone clinical chemists from 158 different hospitals and asked them to transmit to the concerned physicians of their hospital a detailed questionnaire for assessing which bone marker(s) is (are) prescribed and for which purpose (s), and if not prescribed, the reason of non prescription. We were able to analyze 309 questionnaires from 89 hospitals including 5 specialties, rheumatology (35.9%), endocrinology (18.1%), gynecology (11.0%), internal medicine (22.0%) and geriatry (12.9%). The results showed large discrepancies between the mode of prescription of a subset of physicians and the guidelines. The most often evoked reason for non prescription was a lack of information about bone markers suggesting a need for teaching courses. This survey has also shown that many physicians do not know exactly which parameters are effectively measured in their hospital and which are addressed to specialized laboratories underlining the importance of the dialogue between clinicians and clinical chemists. We propose that in a given hospital, the present article may serve as a basis for a discussion between clinicians and biologists about the development and/or the optimization of the measurements of these markers of bone turnover.
Assuntos
Biomarcadores , Remodelação Óssea , Fidelidade a Diretrizes/estatística & dados numéricos , Corpo Clínico Hospitalar/estatística & dados numéricos , Osteoporose/diagnóstico , Osteoporose/metabolismo , Guias de Prática Clínica como Assunto , Padrões de Prática Médica/estatística & dados numéricos , Prescrições/estatística & dados numéricos , Biomarcadores/sangue , Biomarcadores/urina , Educação Médica , Educação Médica Continuada , França , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Corpo Clínico Hospitalar/educação , Corpo Clínico Hospitalar/psicologia , Medicina/estatística & dados numéricos , Avaliação das Necessidades , Seleção de Pacientes , Especialização , Inquéritos e QuestionáriosRESUMO
Biochemical markers of bone turnover have been developed over the past 20 years that are more specific for bone tissue than conventional ones such as total alkaline phosphatase and urinary hydroxyproline. They have been widely used in clinical research and in clinical trials of new therapies as secondary end points of treatment efficacy. Most of the interest has been devoted to their use in postmenopausal osteoporosis, a condition characterized by subtle modifications of bone metabolism that cannot be detected readily by conventional markers of bone turnover. Although several recent studies have suggested that biochemical markers may be used for the management of the individual patient in routine clinical practice, this has not been clearly defined and is a matter of debate. Because of the crucial importance to clarify this issue, the Société Francaise de Biologie Clinique prompted an expert committee to summarize the available data and to make recommendations. The following paper includes a review on the biochemical and analytical aspects of the markers of bone formation and resorption and on the sources of variability such as sex, age, menstrual cycle, pregnancy and lactation, physical activity, seasonal variation and effects of diseases and treatments. We will also describe the effects of pre-analytical factors on the measurements of the different markers. Finally based on that review, we will make practical recommendations for the use of these markers in order to minimize the variability of the measurements and improve the clinical interpretation of the data.
Assuntos
Biomarcadores , Remodelação Óssea , Osso e Ossos/metabolismo , Osteoporose/diagnóstico , Adolescente , Adulto , Fatores Etários , Fosfatase Alcalina/análise , Doenças Ósseas/metabolismo , Reabsorção Óssea , Osso e Ossos/enzimologia , Cálcio/urina , Criança , Colágeno/metabolismo , Anticoncepcionais Orais/farmacologia , Exercício Físico , Feminino , Humanos , Hidroxiprolina/urina , Imobilização , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Osteocalcina/sangue , Osteoporose/tratamento farmacológico , Osteoporose/metabolismo , Osteoporose Pós-Menopausa/diagnóstico , Osteoporose Pós-Menopausa/tratamento farmacológico , Osteoporose Pós-Menopausa/metabolismo , Gravidez , Estações do Ano , Fatores Sexuais , Manejo de EspécimesRESUMO
Many clinical trials have been engaged to prove the benefits of new drugs in the treatment of hematological tumours. However, no real progress have occurred in diseases such as multiple myeloma, the association of melphalan and prednisone is still the mainstay of the treatment. During all these years, the family of glucocorticoids have not been totally studied. Their efficiency in the cure of lymphoid malignancies has been early recognised, but still to be based on their anti-inflammatory potency for the dosages. Only few works reported the comparison between members of this family. We demonstrate in this work, in vitro, with a cell line of medium sensibility and a B cell of tumoral origin grew up in our laboratory, that exists some differences in the anti-neoplastic potency of the more commonly used corticoids. If the order in which we can class these drugs is not surprising and empirically known, the importance of the differences observed need a special attention. We also found that these drugs might have stimulatory effects, at various degree in function of their concentrations, on the proliferation of the B cell lines. Theses side effects coupled to the efficiency variations of each corticoid present the need of paying more attention to the choice of the molecule implied in the chemotherapy.
Assuntos
Linfócitos B/efeitos dos fármacos , Glucocorticoides/toxicidade , Síndromes Mielodisplásicas/metabolismo , Síndromes Mielodisplásicas/patologia , Linfócitos B/patologia , Sobrevivência Celular/efeitos dos fármacos , Humanos , Cadeias lambda de Imunoglobulina/biossíntese , Interleucina-6/biossíntese , Síndromes Mielodisplásicas/tratamento farmacológico , Receptores de Glucocorticoides/biossíntese , Receptores de Interleucina-6/biossíntese , Fatores de Tempo , Células Tumorais CultivadasRESUMO
The expression of dystrophin-protein 71 (Dp71) was investigated during nerve growth factor (NGF) induced differentiation of PC12 cells. A semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) assay was designed to measure Dp71 mRNA, whereas the Dp71 protein amount was evaluated by immunoblot analysis using an anti-dystrophin monoclonal antibody. Comparison with control cultures showed that Dp71 mRNA and protein levels increased in parallel with NGF treatment peaking with increments of 60% and 1.4 times, respectively. The upregulation of Dp71 expression during PC12 cells differentiation point at PC12 cells as a suitable model for studying the function of Dp71 in neuronal cells.